Premium
Clinical Outcomes in Patients with Parkinson's Disease Treated with a Monoamine Oxidase Type‐B inhibitor: A Cross‐Sectional, Cohort Study
Author(s) -
Dashtipour Khashayar,
Chen Jack J.,
Kani Camellia,
Bahjri Khaled,
Ghamsary Mark
Publication year - 2015
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1611
Subject(s) - cohort , parkinson's disease , medicine , monoamine oxidase b , cross sectional study , cohort study , monoamine oxidase , disease , psychiatry , chemistry , pathology , enzyme , biochemistry
Study Objective To evaluate the long‐term risk of developing cognitive symptoms (e.g., dementia, hallucinations), dyskinesia, falls, and freezing of gait (FoG) in patients with Parkinson's disease ( PD ) who received monoamine oxidase type B inhibitors ( MAOB ‐Is) compared with patients who had never received MAOB ‐Is. Design Retrospective, cross‐sectional, cohort study. Setting Academic movement disorders clinic. Patients One hundred eighty‐one patients with idiopathic PD who were receiving MAOB ‐I therapy on a long‐term basis for a minimum of 1 year ( MAOB ‐I current‐user cohort) and 121 patients with idiopathic PD who had never received MAOB ‐I therapy ( MAOB ‐I never‐user cohort [control group]) between January 1, 1996, and November 30, 2011. Measurements and Main Results The five study outcome variables were dementia, dyskinesia, falls, FoG, and hallucinations. Baseline and outcome data were collected from medical records. Patients in the MAOB ‐I current‐user group were included only if absence of the specified outcomes was documented at baseline. Adjusted multiple logistic regression analyses were performed to calculate the odds ratios ( OR s) for MAOB ‐I use versus never use on clinical outcomes. MAOB ‐I treatment was associated with a 44.7% reduced risk of dyskinesia (adjusted OR 0.553, 95% confidence interval 0.314–0.976, p=0.041), with the greatest risk reduction observed after 2 years of treatment. No significant association was noted with MAOB ‐I use and development of dementia, falls, FoG, or hallucinations. Conclusion Long‐term use of MAOB ‐I therapy was associated with reduced risk of dyskinesia in patients with PD .